Replimune Group, Inc. (REPL)
NASDAQ: REPL · IEX Real-Time Price · USD
8.17
-0.08 (-0.97%)
At close: Mar 28, 2024, 4:00 PM
8.37
+0.20 (2.45%)
After-hours: Mar 28, 2024, 5:38 PM EDT
Replimune Group Market Cap
Replimune Group has a market cap or net worth of $506.45 million as of March 28, 2024. Its market cap has decreased by -55.30% in one year.
Market Cap
506.45M
Enterprise Value
114.27M
1-Year Change
-55.30%
Ranking
Category
Stock Price
$8.17
Market Cap Chart
Since July 20, 2018, Replimune Group's market cap has increased from $467.50M to $506.45M, an increase of 8.33%. That is a compound annual growth rate of 1.42%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 27, 2024 | 506.40M | 7.27% |
Mar 26, 2024 | 472.10M | -4.47% |
Mar 25, 2024 | 494.20M | -1.83% |
Mar 22, 2024 | 503.40M | - |
Mar 21, 2024 | 503.40M | 1.10% |
Mar 20, 2024 | 497.90M | -1.81% |
Mar 19, 2024 | 507.10M | -0.24% |
Mar 18, 2024 | 508.30M | -2.92% |
Mar 15, 2024 | 523.60M | -3.52% |
Mar 14, 2024 | 542.70M | -1.56% |
Mar 13, 2024 | 551.30M | 3.22% |
Mar 12, 2024 | 534.10M | -1.69% |
Mar 11, 2024 | 543.30M | -1.98% |
Mar 8, 2024 | 554.30M | 2.14% |
Mar 7, 2024 | 542.70M | -1.88% |
Mar 6, 2024 | 553.10M | 4.65% |
Mar 5, 2024 | 528.50M | -3.05% |
Mar 4, 2024 | 545.10M | -1.00% |
Mar 1, 2024 | 550.60M | 4.54% |
Feb 29, 2024 | 526.70M | -1.50% |
Feb 28, 2024 | 534.70M | -1.69% |
Feb 27, 2024 | 543.90M | 2.91% |
Feb 26, 2024 | 528.50M | 4.61% |
Feb 23, 2024 | 505.20M | 3.52% |
Feb 22, 2024 | 488.00M | 4.05% |
View and export this data all the way back to 2018.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Solid Biosciences | 512.74M |
Orthofix Medical | 507.23M |
SNDL Inc. | 497.23M |
Nevro | 497.01M |
CareDx | 495.52M |
IGM Biosciences | 493.81M |
Lyell Immunopharma | 492.95M |
Revance Therapeutics | 489.82M |